Curadev Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.26 Cr
as on 16-11-2024
- Company Age 15 Year, 9 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 25.00 Cr
as on 16-11-2024
- Satisfied Charges ₹ 16.00 Cr
as on 16-11-2024
- Revenue -63.26%
(FY 2023)
- Profit -580.63%
(FY 2023)
- Ebitda -125.62%
(FY 2023)
- Net Worth -50.86%
(FY 2023)
- Total Assets -47.85%
(FY 2023)
About Curadev Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 1.26 Cr.
The company currently has active open charges totaling ₹25.00 Cr. The company has closed loans amounting to ₹16.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Manish Tandon, Arjun Surya, and Sandeep Gupta serve as directors at the Company.
- CIN/LLPIN
U33111DL2010PTC197755
- Company No.
197755
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Curadev Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Tandon  | Director | 07-Jan-2010 | Current |
| Arjun Surya | Director | 07-Jan-2010 | Current |
Sandeep Gupta  | Director | 03-Feb-2014 | Current |
Financial Performance of Curadev Pharma.
Curadev Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 63.26% decrease. The company also saw a substantial fall in profitability, with a 580.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 50.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curadev Pharma?
In 2023, Curadev Pharma had a public holding of 17.38%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 Feb 2021 | ₹25.00 Cr | Open |
Hdfc Bank Limited Creation Date: 24 Apr 2017 | ₹10.00 Cr | Satisfied |
Icici Bank Limited Creation Date: 25 Mar 2011 | ₹6.00 Cr | Satisfied |
How Many Employees Work at Curadev Pharma?
Curadev Pharma has a workforce of 46 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curadev Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curadev Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
